Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Morgan

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Cancer Research|May 8, 2007
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screenSusan E Morgan-Lappe, Lora A Tucker, Xiaoli Huang, et al.
Molecular Cancer Therapeutics|January 24, 2007
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cellsAparna V Sarthy, Susan E Morgan-Lappe, Dorothy Zakula, et al.
Cancer Research|February 7, 2007
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737Stephen K Tahir, Xiufen Yang, Mark G Anderson, et al.
Molecular Cancer Therapeutics|July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsMichael S Gordon, John Nemunaitis, Minal Barve, et al.
Molecular Cancer Therapeutics|March 30, 2018
ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical ModelsYingchun Li, Jonathan A Hickson, Dominic J Ambrosi, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Cancer Research|May 17, 2018
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug ConjugatesJames W Purcell, Sonia G Tanlimco, Jonathan Hickson, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Cancer Research|May 8, 2007
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screenSusan E Morgan-Lappe, Lora A Tucker, Xiaoli Huang, et al.
Molecular Cancer Therapeutics|January 24, 2007
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cellsAparna V Sarthy, Susan E Morgan-Lappe, Dorothy Zakula, et al.
Cancer Research|February 7, 2007
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737Stephen K Tahir, Xiufen Yang, Mark G Anderson, et al.
Molecular Cancer Therapeutics|July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsMichael S Gordon, John Nemunaitis, Minal Barve, et al.
Molecular Cancer Therapeutics|March 30, 2018
ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical ModelsYingchun Li, Jonathan A Hickson, Dominic J Ambrosi, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Cancer Research|May 17, 2018
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug ConjugatesJames W Purcell, Sonia G Tanlimco, Jonathan Hickson, et al.
Pageof 7